ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 58 citations in OpenAlex.
- Genomic Biomarker for Prostate Cancer Focal Therapy: Post Hoc Assessment of a Phase II Clinical Trial.JCO precision oncology · 2025Trial
- Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy.Signal transduction and targeted therapy · 2026Article
- Determinants of response to neoadjuvant chemotherapy in breast cancer: Integrated roles of immune pathways, DNA damage response, and cell cycle regulators.Molecular biology reports · 2026Review
- Bidirectional coupling among EMT, AXL-RB1 signaling and lineage switch drives resistance to osimertinib and worse clinical outcomes in NSCLC.bioRxiv : the preprint server for biology · 2026Article
- Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Current and Emerging Protein Biomarkers for the Diagnosis and Prognosis of Head and Neck Cancer.Genes · 2025Review
- Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance.The Prostate · 2025Article
- RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.Scientific reports · 2025Article
- Allelic expression patterns of imprinted and non-imprinted genes in cancer cell lines from multiple histologies.Clinical epigenetics · 2025Article
- Proteogenomic discovery ofScience advances · 2025Article
- p16 Immunohistochemical Patterns in Triple-Negative Breast Cancer: Clinical and Genomic Similarities of the p16 Diffuse Pattern to pRB Deficiency.Pathobiology : journal of immunopathology, molecular and cellular biology · 2025Article
- The Traditional Chinese Medicine FormulaJournal of Cancer · 2025Article
- Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.Nature communications · 2024Article
- Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Casein Kinase 1α-A Target for Prostate Cancer Therapy?Cancers · 2024Review
- Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer.NPJ genomic medicine · 2024Article
- ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling.Cancers · 2024Article
- RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping.Life science alliance · 2023Article
- Concurrent RB1 loss andmedRxiv : the preprint server for health sciences · 2023Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 10 institutions in 2 countries.
Funding
Abstract
purposeRb-pathway disruption is of great clinical interest, as it has been shown to predict outcomes in multiple cancers. We sought to develop a transcriptomic signature for detecting biallelic EXPERIMENTAL
designWe utilized data from the Cancer Cell Line Encyclopedia (
resultsRBS outperformed the leading existing signature for detecting
conclusionsOur study provides the first validated tool to assess
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.